Alnylam Pharmaceuticals, Inc. (ALNY)
291.37
-1.80
(-0.61%)
USD |
NASDAQ |
Jun 26, 16:00
291.58
+0.20
(+0.07%)
After-Hours: 20:00
Alnylam Pharmaceuticals Cash from Financing (TTM) : -333.56M for March 31, 2026
Cash from Financing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | -333.56M |
| December 31, 2025 | -303.19M |
| September 30, 2025 | -317.51M |
| June 30, 2025 | 233.59M |
| March 31, 2025 | 311.33M |
| December 31, 2024 | 294.16M |
| September 30, 2024 | 302.39M |
| June 30, 2024 | 232.77M |
| March 31, 2024 | 154.67M |
| December 31, 2023 | 172.13M |
| September 30, 2023 | 196.34M |
| June 30, 2023 | 460.22M |
| March 31, 2023 | 437.17M |
| December 31, 2022 | 425.75M |
| September 30, 2022 | 654.61M |
| June 30, 2022 | 931.42M |
| March 31, 2022 | 1.231B |
| December 31, 2021 | 1.247B |
| September 30, 2021 | 1.173B |
| June 30, 2021 | 633.08M |
| March 31, 2021 | 992.29M |
| December 31, 2020 | 994.98M |
| September 30, 2020 | 817.37M |
| June 30, 2020 | 762.52M |
| March 31, 2020 | 486.12M |
| Date | Value |
|---|---|
| December 31, 2019 | 823.18M |
| September 30, 2019 | 788.22M |
| June 30, 2019 | 821.91M |
| March 31, 2019 | 414.88M |
| December 31, 2018 | 65.47M |
| September 30, 2018 | 767.04M |
| June 30, 2018 | 782.97M |
| March 31, 2018 | 1.164B |
| December 31, 2017 | 1.125B |
| September 30, 2017 | 421.02M |
| June 30, 2017 | 396.46M |
| March 31, 2017 | 164.48M |
| December 31, 2016 | 177.83M |
| September 30, 2016 | 181.22M |
| June 30, 2016 | 180.52M |
| March 31, 2016 | 33.26M |
| December 31, 2015 | 616.18M |
| September 30, 2015 | 617.37M |
| June 30, 2015 | 618.51M |
| March 31, 2015 | 616.57M |
| December 31, 2014 | 736.46M |
| September 30, 2014 | 736.46M |
| June 30, 2014 | 742.75M |
| March 31, 2014 | 741.59M |
| December 31, 2013 | 200.93M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (TTM) Benchmarks
| Ionis Pharmaceuticals, Inc. | 730.90M |
| BioMarin Pharmaceutical, Inc. | 809.55M |
| Insmed, Inc. | 954.59M |
| Regeneron Pharmaceuticals, Inc. | -3.428B |
| Vertex Pharmaceuticals, Inc. | -2.120B |